<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Post-<z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0000716'>depression</z:hpo> (PSD) is one of the psychiatric complications after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Present study was conducted to elucidate the protective effect of <z:chebi fb="0" ids="9123">sertraline</z:chebi> and possible involvement of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> mechanism against transient global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> induced <z:mp ids='MP_0002573'>behavioral despair</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> was given twice for 5 min at 10 min interval followed by 96 h reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> reperfusion significantly increased immobility period and decreased resistance to lateral push as compared to sham-operated group </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> reperfusion caused significant oxidative damage and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> enzyme complex (I-III) dysfunction as compared to sham group </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="9123">Sertraline</z:chebi> (5 and 10mg/kg) treatment significantly reduced immobility period, increased resistance to lateral push, attenuated oxidative damage and restored <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> enzyme complex activities as compared to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> group </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="16467,29952">L-Arginine</z:chebi> (100mg/kg) or sildenafil (5mg/kg) pretreatment with <z:chebi fb="0" ids="9123">sertraline</z:chebi> (5mg/kg) significantly reversed the protective effect of <z:chebi fb="0" ids="9123">sertraline</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>However, L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (10mg/kg) or 7NI (10mg/kg) pretreatment with <z:chebi fb="0" ids="9123">sertraline</z:chebi> (5mg/kg) significantly potentiated their protective effect which were significant as compared to their effect alone </plain></SENT>
<SENT sid="8" pm="."><plain>The present study shows that nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> modulation is involved in the protective effect of <z:chebi fb="0" ids="9123">sertraline</z:chebi> </plain></SENT>
</text></document>